BCMA-Targeted CAR T-Cell Therapy: Where Are We And Where Are We Going?

Download this slideset based on the content from a live stream CCO webinar from Thomas G. Martin, MD, on how to integrate CAR T-cell therapy for patients with relapsed/refractory multiple myeloma.
Thomas G. Martin, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 490 KB
Released: September 10, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
GlaxoSmithKline
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

Global perspective of key studies presented at ASCO, EHA, ICML 2021 from an international expert in CLL from Clinical Care Options (CCO)

George Follows, BM, BCh, PhD Released: September 17, 2021

Analysis of key studies in hematologic malignancies from ASCO 2021 presented by Drs. Ian Flinn, Shaji Kumar, and Eunice Wang, as reported by Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Shaji K. Kumar, MD Eunice S. Wang, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: September 13, 2021 Expired: September 12, 2022

Gain key clinical insights from Sagar Lonial, MD on anti-BCMA ADCs for R/R MM, from Clinical Care Options (CCO)

Sagar Lonial, MD Released: September 10, 2021

Gain key clinical insights from Suzanne Lentzsch, MD, PhD on anti-BCMA bispecific antibodies for R/R MM, from Clinical Care Options (CCO)

Suzanne Lentzsch, MD, PhD Released: September 10, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue